找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Hot Carriers in Semiconductors; Karl Hess,Jean-Pierre Leburton,Umberto Ravaioli Book 1996 Plenum Press, New York 1996 Exciton.MOSFET.Semic

[復(fù)制鏈接]
樓主: Extraneous
51#
發(fā)表于 2025-3-30 09:29:33 | 只看該作者
52#
發(fā)表于 2025-3-30 14:00:30 | 只看該作者
53#
發(fā)表于 2025-3-30 20:14:15 | 只看該作者
F. Yang,G. R. Hayes,R. T. Phillips,K. P. O’Donnell regimens including high dose cytarabine are appropriate for patients with myeloid EML. Presence of EML should not be used alone to determine need for stem cell transplant (SCT). Risk-adapted treatment should utilize genetic markers and disease response that includes assessment of remission in EML s
54#
發(fā)表于 2025-3-30 22:46:40 | 只看該作者
R. Hellmann,A. Euteneur,S. G. Hense,J. Feldmann,P. Thomas,E. O. G?bel,A. Waag,G. Landwehr9–1886, 2020). This correlates with approximately one in every three pediatric AML patients dying, and the price for cure among survivors includes a significant increase in long-term chronic health conditions (Bhatt et al., Leukemia 35(8):2258–2273, 2021). Further improvement is badly needed. Within
55#
發(fā)表于 2025-3-31 00:53:36 | 只看該作者
Yu. L. Ivanov,G. V. Churakov,V. M. Ustinov,A. E. Zhukov regimens including high dose cytarabine are appropriate for patients with myeloid EML. Presence of EML should not be used alone to determine need for stem cell transplant (SCT). Risk-adapted treatment should utilize genetic markers and disease response that includes assessment of remission in EML s
56#
發(fā)表于 2025-3-31 05:59:35 | 只看該作者
57#
發(fā)表于 2025-3-31 11:09:53 | 只看該作者
58#
發(fā)表于 2025-3-31 15:22:00 | 只看該作者
59#
發(fā)表于 2025-3-31 18:10:49 | 只看該作者
60#
發(fā)表于 2025-4-1 01:16:15 | 只看該作者
Jürgen Schilp,Tilmann Kuhnf existing legislation is required in order to make the EU liability framework fit for the current and forthcoming technological and commercial developments. In addition, this chapter provides an extensive review of the Commission’s 2020 Report on the safety and liability implications of AI, IoT and
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 19:17
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
祁连县| 常德市| 客服| 陈巴尔虎旗| 宜兰市| 廉江市| 大关县| 綦江县| 盐山县| 嘉义市| 手机| 延庆县| 格尔木市| 宽城| 临漳县| 天台县| 康保县| 林周县| 连平县| 桐柏县| 彭阳县| 云和县| 德庆县| 洪洞县| 汝南县| 江川县| 金寨县| 琼结县| 长治市| 芦溪县| 南澳县| 黎平县| 长岭县| 常德市| 盐边县| 芦山县| 昌宁县| 佛冈县| 花垣县| 上饶市| 汤原县|